PMID- 32648169
OWN - NLM
STAT- MEDLINE
DCOM- 20210608
LR  - 20210608
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Linking)
VI  - 34
IP  - 6
DP  - 2020 Dec
TI  - Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic 
      Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
PG  - 755-762
LID - 10.1007/s10557-020-07036-3 [doi]
AB  - PURPOSE: Sacubitril/valsartan has been demonstrated to improve prognosis and 
      outcomes in heart failure with reduced ejection fraction (HFrEF) patients. We 
      sought to compare the improvement in cardiac function between non-ischaemic and 
      ischaemic cardiomyopathy for patients receiving sacubitril/valsartan. METHODS: We 
      conducted a single centre prospective cohort survey of patients reviewed in the 
      Heart Function Clinic between February 2017 and January 2018. Functional 
      evaluation and measurement of biochemical and echocardiographic parameters 
      occurred before the initiation of sacubitril/valsartan, and after 3 months of 
      treatment. RESULTS: We identified 52 patients (26 non-ischaemic and 26 ischaemic 
      cardiomyopathy) suitable for treatment with sacubitril/valsartan. Treatment was 
      followed by a significant decrease in a New York Heart Association (NYHA) class 
      in both patients with non-ischaemic (2.3 +/- 0.6 vs. 1.6 +/- 0.7, P < 0.001) and 
      ischaemic cardiomyopathy (2.3 +/- 0.5 vs. 1.5 +/- 0.6, P < 0.001), along with an 
      increase in ejection fraction in both patients with non-ischaemic (26.2% +/- 6.5% 
      vs. 37.2% +/- 13.8%, P < 0.001) and ischaemic cardiomyopathy (28.1% +/- 5.7% vs. 
      31.5% +/- 8.4%, P = 0.007). The improvement in ejection fraction was significantly 
      greater in the patients with non-ischaemic cardiomyopathy compared to those with 
      ischaemic cardiomyopathy (10.7% +/- 13.0% vs. 3.9% +/- 6.0%, P = 0.023). CONCLUSION: 
      Our study suggests that treatment with sacubitril/valsartan in patients with 
      non-ischaemic cardiomyopathy is followed by a greater improvement in ejection 
      fraction than in patients with ischaemic cardiomyopathy.
FAU - Ioannou, Adam
AU  - Ioannou A
AUID- ORCID: 0000-0001-5017-8657
AD  - Royal Free NHS Foundation Trust, London, UK.
FAU - Metaxa, Sofia
AU  - Metaxa S
AD  - Department of Cardiology, Wexham Park Hospital, Wexham Street, Slough, UK.
FAU - Simon, Steny
AU  - Simon S
AD  - Department of Cardiology, Wexham Park Hospital, Wexham Street, Slough, UK.
FAU - Mandal, Amit K J
AU  - Mandal AKJ
AD  - Department of Cardiology, Wexham Park Hospital, Wexham Street, Slough, UK.
FAU - Missouris, Constantinos G
AU  - Missouris CG
AD  - Department of Cardiology, Wexham Park Hospital, Wexham Street, Slough, UK. 
      dinos.missouris@nhs.uk.
AD  - University of Cyprus Medical School, Nicosia, Cyprus. dinos.missouris@nhs.uk.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20200709
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminobutyrates/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Biphenyl Compounds/*therapeutic use
MH  - Cardiomyopathies/diagnosis/*drug therapy/etiology/physiopathology
MH  - Drug Combinations
MH  - Female
MH  - Heart Failure/diagnosis/*drug therapy/etiology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Ischemia/*complications
MH  - Neprilysin/antagonists & inhibitors
MH  - Prospective Studies
MH  - Protease Inhibitors/*therapeutic use
MH  - Recovery of Function
MH  - Stroke Volume/*drug effects
MH  - Systole
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan/*therapeutic use
MH  - Ventricular Function, Left/*drug effects
OTO - NOTNLM
OT  - Cardiomyopathy
OT  - Ejection fraction
OT  - Heart failure
OT  - Sacubitril/valsartan
EDAT- 2020/07/11 06:00
MHDA- 2021/06/09 06:00
CRDT- 2020/07/11 06:00
PHST- 2020/07/05 00:00 [accepted]
PHST- 2020/07/11 06:00 [pubmed]
PHST- 2021/06/09 06:00 [medline]
PHST- 2020/07/11 06:00 [entrez]
AID - 10.1007/s10557-020-07036-3 [pii]
AID - 10.1007/s10557-020-07036-3 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2020 Dec;34(6):755-762. doi: 10.1007/s10557-020-07036-3. 
      Epub 2020 Jul 9.